ModifiedUnitedHealthcarePolicy CS086PA.Y

Occipital Nerve Injections and Ablation (Including Occipital Neuralgia and Headache) (for Pennsylvania Only)

Policy governing coverage and medical necessity of occipital nerve injections, neurolytic ablation, and related procedures for occipital neuralgia and headache for members in Pennsylvania.

Policy Summary

PayerUnitedHealthcare

PolicyOccipital Nerve Injections and Ablation (Including Occipital Neuralgia and Headache) (for Pennsylvania Only)

Policy CodePolicy CS086PA.Y

Change TypeDefinitions addedevidence & references updated

Effective DateOct 1, 2025

Next Review Date

Key ActionObtain and document prior conservative therapy and diagnostic block response (e.g., ≥50% relief) before requesting authorization for RFA or implantable neurostimulation.

SourceLink

POLICY UPDATE CHANGES

Added definitions for the Migraine Disability Assessment Test (MIDAS) and Migraine-Specific Quality of Life Questionnaire (MSQ).

Clinical Evidence and References sections updated to reflect the most current information.

Previous policy version CS086PA.X archived.

PA-onlystate-specific policy application

20+ codesprocedure and diagnosis codes referenced

multiple RCTsevidence base referenced

mixed evidence

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

GONB summary finding

lowevidence certainty (preventive chronic migraine)

2new PRO definitions added

Coverage Criteria and Medical Necessity

Medically necessary for malignancy-related head/neck pain

Covered when for pain due to malignancy of the head and neck:

Occipital nerve injection/ablation for malignant pain: Injection of local anesthetics and/or steroids used as greater occipital nerve blocks (GONBs) and occipital nerve ablation (destruction by neurolytic agent) are proven and medically necessary for treating pain due to malignancy involving the head and neck.

From Coverage Rationale; applies specifically to pain due to malignancy.

Unproven / Not medically necessary for ON or headaches

Declared not medically necessary/unproven for occipital neuralgia or headaches (insufficient evidence):

Unproven interventions for ON/headache: Injection of local anesthetics and/or steroids used as GONBs; neurostimulation/electrical stimulation; occipital neurectomy; partial posterior intradural C1-C3 rhizotomy; radiofrequency ablation (thermal or pulsed) or denervation; rhizotomy of C1-C3 dorsal roots; surgical decompression of second cervical nerve root and ganglion; surgical decompression of the greater occipital nerve.

Procedures listed as unproven and not medically necessary for diagnosing and/or treating occipital neuralgia or headaches except when related to malignancy as specified.

GONB — therapeutic coverage logic

GONB coverage considerations based on available evidence:

Short-term therapeutic effect: Randomized trials and meta-analyses show GONB with local anesthetic can reduce headache intensity and frequency in the short term (hours to ~1 month) versus placebo in some populations.

Evidence quality often low and heterogeneous; corticosteroid addition generally not shown to add benefit in some analyses.

Evidence quality and duration limits: The body of evidence is frequently rated low quality with small sample sizes and short follow-up; long-term preventive benefit for chronic migraine is not established.

Hayes and other reviews conclude larger, longer RCTs are needed.

Surgical treatment — coverage logic

Surgical interventions coverage considerations:

Surgery outcomes and uncertainty: Selected systematic reviews report reductions in headache frequency and severity after migraine or occipital surgery, but overall evidence is limited by small studies, heterogeneity, and risk of bias; long-term efficacy remains unproven.

Neuroplasty has no RCT evidence; occipital neurectomy and decompression lack sufficient high-quality trials.

Prior conservative management: Surgical procedures should be considered only after failure of conservative management and less invasive interventions given limited evidence base.

Reviews recommend cautious patient selection and additional RCTs.

Nerve decompression and neurectomy

Evidence and coverage stance for nerve decompression and neurectomy

Nerve decompression/neurectomy coverage: Evidence is insufficient to conclude occipital neurectomy or nerve decompression is effective for headaches; long-term efficacy not established in well-designed trials.

Systematic reviews report low-quality evidence and lack of RCTs or consistent outcomes.

Radiofrequency ablation (RFA)

Evidence and coverage stance for radiofrequency ablation (RFA)

RFA evidence summary: Published studies show variable short-term benefit of RFA for headaches and occipital neuralgia, including some RCTs and multiple observational reports; however, evidence is heterogeneous and insufficient to conclusively establish long-term effectiveness for all indications.

Some systematic reviews report favorable short-term outcomes but call for larger RCTs.

Candidate selection associated with better outcomes: Individuals with positive response to diagnostic occipital or C2 blocks are more likely to have benefit from RFA or pulsed RFA.>=50% relief after diagnostic block typical in studies

Referenced in several retrospective and prospective studies.

Neurostimulation / electrical stimulation

Evidence and coverage stance for neurostimulation / ONS

Neurostimulation evidence summary: Studies are limited and methodologically flawed; reported responder rates vary widely and adverse events include lead migration/fracture and local pain; no well-designed RCTs compare ONS to established treatments or sham for many indications.

Further large, long-term RCTs are needed.

Criteria for consideration of implantable occipital nerve stimulation

Evidence-based selection and implantation considerations noted in the literature

ONS patient selection: Permanent ONS implantation typically follows documented failure of conservative therapies AND a positive temporary trial (commonly defined as ≥50% pain reduction during the trial).≥50% trial pain reduction

Based on multiple studies and Hayes assessments

Criteria for consideration of pulsed radiofrequency / pulsed radiofrequency neuromodulation

Interpretation of evidence for radiofrequency and pulsed radiofrequency treatments

PRF/PRFT evidence summary: Small studies and systematic reviews report symptomatic relief for some patients from pulsed radiofrequency (PRF/PRFN), but evidence quality is low and optimal targets/settings are unclear.Consider only after conservative therapy fails

Large RCTs and long-term follow-up are needed.

Criteria for consideration of noninvasive neuromodulation

Noninvasive neuromodulation findings

REN and combined occipital/trigeminal noninvasive stimulation: Randomized trials show remote electrical neuromodulation (REN) reduces migraine days versus sham and combined occipital/trigeminal noninvasive stimulation provides acute pain relief versus sham; these may be considered non-pharmacologic preventive or acute therapy alternatives.Device-specific trial evidence

No serious device-related adverse events reported in REN trial.

Coverage considerations

Evidence and guideline-based considerations for offering neurostimulation or RFN

Occipital nerve RFN candidacy: Use for posterior head pain due to occipital neuralgia after diagnostic occipital nerve block identifies the nerve as the pain generator; other etiologies should be ruled out with MRI/CT prior to RFN.

Best practices favor PRFN and diagnostic blocks prior to RFN.

ONS candidacy: ONS may be considered for medically refractory occipital neuralgia or chronic cluster headache refractory to available therapies, recognizing evidence is low-quality and complications are common.

Congress of Neurological Surgeons: Level III for ONS in refractory ON; Hayes rating D2 for chronic cluster headache.

Guideline-based coverage considerations

Guideline-based coverage considerations and restrictions

Insufficient evidence for many neuromodulation techniques: VA/DoD and other guideline bodies state there is insufficient evidence to recommend for or against many neuromodulation techniques for migraine and headache (includes non-invasive vagus nerve stimulation, supraorbital/external trigeminal stimulation, remote electrical neurostimulation, external combined occipital and trigeminal systems, rTMS, and transcranial direct current stimulation).

Documentation of clinical rationale and specialist involvement recommended.

Procedures requiring special arrangements: NICE recommends certain procedures (e.g., transcutaneous SON stimulation, occipital nerve stimulation, SPG stimulation) should only be used with special arrangements for clinical governance, consent, audit or research and selection by clinicians with expertise in migraine management.

Coverage may be conditional on these arrangements or participation in audit/research or tertiary center care.

Device regulatory status informational: Devices used for RFA and electrical stimulation are regulated (FDA 510(k) or De Novo pathways); FDA clearance is informational and not a sole basis for coverage.

Procedures explicitly listed in the policy as unproven and not medically necessary for diagnosing or treating occipital neuralgia or headaches (including migraine and cervicogenic headache) are excluded from medically necessary coverage except where specifically noted for malignancy-related pain. Examples enumerated in the policy include greater occipital nerve blocks (when claimed as definitive therapy for these diagnoses), neurostimulation/electrical stimulation, occipital neurectomy, partial posterior intradural C1–C3 rhizotomy, radiofrequency ablation (thermal or pulsed) or denervation, rhizotomy of C1–C3 dorsal roots, and surgical decompression of the second cervical nerve root/ganglion or greater occipital nerve.

Randomized trials and systematic reviews indicate that greater occipital nerve blocks (GONB) with local anesthetic can provide short-term reductions in headache intensity and frequency versus placebo in some populations, but the overall evidence quality is low and heterogeneous. The policy notes there is little to no evidence supporting routine chronic or repeat use of GONB for long‑term prevention of chronic migraine, and larger well‑designed trials with longer follow-up are needed to define any preventive role.

Surgical approaches such as occipital neurectomy, nerve decompression, dorsal nerve root section, partial posterior rhizotomy, neuroplasty, and related procedures lack high‑quality randomized controlled trial evidence demonstrating sustained long‑term benefit. The policy therefore considers these procedures experimental/insufficient and not medically necessary for routine treatment of occipital neuralgia or cervicogenic headache outside of clearly documented, exceptional circumstances.

Evidence for occipital nerve stimulation (ONS) and other implantable or external neurostimulation modalities is limited, heterogeneous, and of generally low quality. Published series report variable responder rates and a not‑insignificant rate of device‑related complications and revisions. As a result, the policy describes neurostimulation modalities as having inconsistent evidence and treats them as investigational or of uncertain benefit for many headache indications.

Clinical guidance cited in the policy recommends that neurostimulation devices be used primarily for medically intractable syndromes managed in tertiary headache centers or within formal research/audit arrangements. Until higher‑quality controlled evidence is available, use of implantable neurostimulation should generally be limited to expert centers or validated study settings with appropriate governance.

Although botulinum toxin A (BTX‑A) is FDA‑approved for certain headache-related indications, the policy clarifies that BTX‑A is not specifically FDA‑approved for cervicogenic headache or occipital neuralgia; its use for these diagnoses is off‑label.

The policy references a range of injection and device‑based procedures addressed in the evidence review and exclusion lists, including: greater occipital nerve blocks (GONBs) with local anesthetic and/or corticosteroid, pulsed and thermal radiofrequency ablation (RFA), occipital nerve ablation by neurolytic agents, occipital neurectomy and nerve decompression, intradural procedures such as partial posterior C1–C3 rhizotomy, and neurostimulation/electrical stimulation (external and implantable).

Systematic reviews and evidence assessments cited in the policy find insufficient high‑quality evidence to conclude that occipital neurectomy, nerve decompression, or neuroplasty produce durable, long‑term benefit for headaches. Given the lack of well‑designed trials with long follow‑up, these surgical interventions are judged to have insufficient evidence for established long‑term effectiveness.

Available literature summarized in the policy indicates a paucity of robust peer‑reviewed trials evaluating nonpulsed (thermal) percutaneous RFA for occipital neuralgia; some evidence syntheses found no RCTs or only limited observational reports. For these reasons, thermal RFA and certain surgical decompression/neurectomy procedures are identified as having insufficient evidence and may be considered not medically necessary when used outside well‑defined refractory contexts with supporting documentation.

The policy states that neurostimulation and electrical stimulation procedures are considered not medically necessary when proposed without documented prior conservative therapy or, for implantable devices, without evidence of an adequate temporary trial response. Documentation of failed conservative management and, for ONS, a positive trial (commonly ≥50% pain reduction) is generally expected before considering permanent implantation.

For chronic cluster headache, the policy highlights that the evidence for occipital nerve stimulation is of very low quality with small study sizes and substantial complication and revision/removal rates. Given these limitations, ONS for chronic cluster headache is considered investigational or not supported for routine use outside of specialist research settings.

Procedure, Diagnosis, and Device Codes

Referenced CPT codes (group 1)CPT

63185	Laminectomy with rhizotomy; 1 or 2 segments.
63190	Laminectomy with rhizotomy; more than 2 segments.
64405	Injection(s), anesthetic agent(s) and/or steroid; greater occipital nerve.
64553	Percutaneous implantation of neurostimulator electrode array; cranial nerve.
64555	Percutaneous implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve).
64568	Open implantation of cranial nerve neurostimulator electrode array and pulse generator.
64570	Removal of cranial nerve neurostimulator electrode array and pulse generator.
64575	Open implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve).
64590	Insertion or replacement of peripheral, sacral, or gastric neurostimulator pulse generator or receiver.
64596	Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed; initial electrode array.

1–10 of 11

1/2

Referenced CPT codes (group 2)CPT

64598	Revision or removal of neurostimulator electrode array, peripheral nerve, with integrated neurostimulator.
64633	Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance; cervical or thoracic, single facet joint.
64634	Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance; each additional facet joint.
64722	Decompression: unspecified nerve(s).
64744	Transection or avulsion of; greater occipital nerve.
64771	Transection or avulsion of other cranial nerve, extradural.
64999	Unlisted procedure, nervous system.

Referenced HCPCS codesHCPCS

A4540	Distal transcutaneous electrical nerve stimulator, stimulates peripheral nerves of the upper arm.
L8679	Implantable neurostimulator, pulse generator, any type.
L8680	Implantable neurostimulator electrode, each.
L8685	Implantable neurostimulator pulse generator, single array, rechargeable, includes extension.

Referenced ICD-10 codesICD-10

C76.0	Malignant neoplasm of head, face and neck.
G89.3	Neoplasm related pain (acute) (chronic).

No explicit codes in this sectionmixed

No codes listed

RFA device product codesmixed

GXD	FDA product code for radiofrequency lesion generators
GXI	FDA product code for radiofrequency lesion probes

Electrical stimulation device product codes / identifiersmixed

GZF	FDA product code for electrical stimulation devices
GZB	FDA product code for electrical stimulation devices
PCC	FDA product code for electrical stimulation devices
K203181	Nerivio Migra De Novo / 510(k) identifier

MIDAS score — interpretation threshold for documentation

MIDAS score interpretationMIDAS questionnaire score categories: 0-5 (none/minimal), 6-10 (mild), 11-20 (moderate), 21+ (severe).

Action thresholdMIDAS score ≥ 6 indicates need for discussion with a provider.

PurposeMIDAS measures headache-related disability by totaling days from questions 1–5 to quantify impact and guide treatment decisions.

Prior Authorization, Documentation, and Operational Requirements

Prior Authorization

Prior Authorization Recommended for Surgical Interventions

Prior authorization is recommended for surgical interventions and implantation procedures (e.g., occipital neurectomy, nerve decompression, neurostimulator implantation, pulse generator placement or removal) to ensure medical necessity, appropriate device selection, and pre-procedure documentation. Prior authorization also helps confirm plan-specific benefit coverage and any plan or state-specific pre-authorization rules.

Affected procedures: decompression/neurectomy (e.g., CPT 64722, 64744, 64771), neurostimulator implantation/removal (e.g., CPT 64553, 64555, 64575, 64590, 64596-64598)
Prior authorization recommended prior to elective surgical or device-based interventions

Note

Confirm Plan-Specific Benefit Requirements

Confirm the member's plan, benefit design, and any federal/state or contractual requirements before scheduling services. Coverage decisions must follow applicable benefit language; in case of conflict, federal/state/contractual requirements govern.

Verify member eligibility and benefits, including any exclusions or limits for implantable neurostimulation or surgical procedures

Conservative Management Expectations Before Invasive Procedures

Conservative therapies generally expected before invasive or surgical interventions unless otherwise clinically indicated.

Initial conservative therapy: Trial of standard conservative therapies (e.g., oral analgesics, antiinflammatory agents, and guideline-directed acute and preventive headache medications) is generally expected prior to considering invasive or surgical interventions.

Policy notes conservative therapies are usual first-line options; injections considered when medications provide insufficient relief.

Document trial and failure of conservative measures prior to surgical authorization

Surgical authorization documentation: Prior authorization for surgical interventions (neurectomy, decompression, neuroplasty) should include documentation of trials and failure of conservative therapies and less-invasive interventions.

Frequency and Repeat Treatment Notes

Four-weekly GONB described in a trial (research context)

Described frequency in trialFour-weekly bilateral GONB (every 4 weeks) for 12 weeks was used in a randomized, double-blind, placebo-controlled trial.

ContextThis frequency was part of a research protocol for chronic migraine prevention and included 4-week baseline and 12-week treatment periods.

Policy frequency stancePolicy notes the four-weekly schedule as used in a trial but does not establish a formal policy frequency limit in this section.

GONB repeat injections — evidence and policy position

Evidence summaryNo established chronic repeat protocol for GONB is supported by high-quality evidence; reviews find only short-term benefit and heterogeneity across studies.

Implication for repeat injections

Imaging and Diagnostic Evaluation

Billing Rule

Imaging guidance referenced for neurolytic/ablation procedures (CPT 64633/64634)

Imaging guidance is described for neurolytic/ablation procedures (CPT 64633/64634) and is commonly used (fluoroscopy or CT); ensure imaging guidance is documented when applicable.

CPT definitions note imaging guidance (fluoroscopy or CT) for destruction by neurolytic agent (64633/64634).
Document fluoroscopic or CT guidance used during neurolytic/ablation procedures when applicable.

Note

Surgical nerve procedures — imaging not specifically mandated in policy extract

No specific imaging requirement is mandated for surgical nerve procedures in this extract, though surgical planning may require imaging; if used, document imaging studies in the record.

Surgical planning and selection may involve imaging but the policy does not specify an imaging protocol for surgical nerve procedures.

Definitions and Outcome Measures

Cervicogenic headache and occipital neuralgia are disorders thought to originate from upper cervical spine pathology or occipital nerve irritation and present as posterior head pain referred from the neck. Management ranges from conservative care (oral analgesics, anti‑inflammatory agents) to targeted injections (e.g., GONB), pulsed or thermal neuromodulation techniques, neurolytic ablation, implantable neurostimulation, and surgical interventions. Radiofrequency ablation creates thermal or pulsed lesions to denervate or modulate peripheral sensory nerves, while GONB involves local anesthetic (often with steroid) injected around the greater occipital nerve for diagnostic or short‑term therapeutic relief.

Cervicogenic Headache — definition

DefinitionCervicogenic headache: referred pain perceived in the head from a source in the neck, caused by disorders of the cervical spine and its components.

Source attributionCause relates to cervical spine bony, disc, or soft tissue elements (American Migraine Foundation, 2016).

Clinical relevanceRecognizing cervicogenic headache guides consideration of neck-focused interventions and imaging when appropriate.

Services Not Covered / Considered Experimental

The policy identifies several interventions as not covered for occipital neuralgia or headaches because they are listed as unproven or not medically necessary: radiofrequency ablation (thermal or pulsed) or denervation, neurostimulation/electrical stimulation, occipital neurectomy, and specified surgical decompressions and rhizotomies. Exceptions for coverage are noted only when procedures are explicitly indicated for malignancy‑related head/neck pain as described elsewhere in the policy.

Policy Revision History

2025-10-01definitions_addedLatest

Added definitions for the Migraine Disability Assessment Test (MIDAS) and the Migraine-Specific Quality of Life Questionnaire (MSQ).

2025-10-01supporting_information_updated

Clinical Evidence and References sections updated to reflect the most current information.

2025-10-01version_archived

Policy Summary

PayerUnitedHealthcare

PolicyOccipital Nerve Injections and Ablation (Including Occipital Neuralgia and Headache) (for Pennsylvania Only)

Policy CodePolicy CS086PA.Y

Change TypeDefinitions addedevidence & references updated

Effective DateOct 1, 2025

Next Review Date

Key ActionObtain and document prior conservative therapy and diagnostic block response (e.g., ≥50% relief) before requesting authorization for RFA or implantable neurostimulation.

SourceLink

On This Page

Nerivio and other device identifiers are noted in policy device sections.

Follow federal, state, and contractual rules when they differ from this policy

Denial Risk

Evidence Insufficiency May Trigger Denial

Insufficient or low-quality evidence for some procedures may lead to coverage denial or requests for additional information. Procedures with limited, conflicting, or low-quality evidence include decompression, neurectomy, radiofrequency ablation (thermal or pulsed in certain indications), and many neurostimulation indications outside well-defined, guideline-supported uses.

Examples of potential denial triggers: lack of prior conservative therapy documentation, absence of diagnostic blockade response, missing device or procedure details, or procedures considered unproven by the policy (see Coverage Rationale)
Insufficient evidence for decompression/neurectomy (no high-quality RCTs; mostly low-level observational data)

Denial Risk

Insufficient Evidence for Decompression/Neurectomy

The evidence base for occipital nerve decompression and occipital neurectomy is limited and inconsistent. Lack of randomized controlled trials and reliance on small observational series or case reports may result in non-coverage unless strong, individualized documentation demonstrating prior treatment response and rationale is provided.

Decompression/neurectomy: limited, low-quality evidence; prior trial data and specialty consultation documentation recommended
May require additional justification due to uncertain long-term efficacy

Denial Risk

High Complication and Device Removal Rates Reported for Some Neurostimulation

High rates of complications and device-related issues have been reported for some implantable neurostimulation therapies (e.g., occipital nerve stimulation): lead migration or fracture, infection, pain at implant site, hardware dysfunction, and need for early battery replacement or device removal. These safety signals can affect coverage decisions and may prompt requests for additional justification or evidence of benefit.

Reported adverse events: lead migration/fracture (≈13%), infection (up to 27% in some series), local pain, hardware dysfunction, and surgical removal/revision rates as reported in the literature
Include prior risk/benefit discussion and complication mitigation plans in documentation for implanted devices

Note

Special Arrangements Requirement

Some procedures or device uses may only be offered under special arrangements (clinical governance, consent, audit, or research) as recommended by external guidance (for example, NICE). When special arrangements are advised, clinicians and healthcare organizations should follow local governance processes, collect and review outcomes, and document informed consent and audit plans.

Follow NICE-style requirements where applicable: governance, consent, outcome audit, and reporting
Document organizational approvals and planned outcome monitoring when required

Documentation Required

Prior Block Response and Conservative Therapy Documentation Expected

Documented response to diagnostic or prior therapeutic nerve blocks and a trial of conservative therapy are expected before many interventional or device-based procedures. For neurostimulation, a positive temporary trial (commonly ≥50% pain reduction) is typically used to select candidates for permanent implantation.

Document prior conservative therapies attempted (e.g., analgesics, anti-inflammatories, preventive medications, physical therapy, injections) and outcomes
Record diagnostic block technique, agents used, percent pain relief, duration of relief, and objective outcome measures (e.g., MIDAS, MSQ)

Documentation Required

Required Documentation Elements to Support Medical Necessity

Required clinical documentation elements include: working diagnosis and relevant ICD codes; history of conservative treatments and duration/outcomes; details of diagnostic blocks (agent, technique, date, percent and duration of pain relief); prior neurostimulator trial details (if applicable) including trial response threshold; device details (manufacturer, model, leads, battery type); procedure type and approach; and specialty consultation notes.

Diagnosis with supporting clinical findings and IHS criteria for occipital neuralgia or cervicogenic headache
Conservative therapy timeline (medications, physical therapy, injections) and documented inadequate response
Diagnostic block report: location, agents, imaging guidance, % pain reduction, duration
Neurostimulation trial documentation: temporary trial data, % reduction (commonly ≥50%), adverse events during trial
Device information for implanted systems: device and lead model numbers, pulse generator type, and surgical implantation details

Documentation Required

Documentation and Evidence—Provide Updated Evidence and References

Maintain and submit current evidence citations, consensus guidance, and policy-relevant literature when requesting coverage for procedures with limited evidence. Ensure documentation reflects updated clinical evidence, specialty society guidelines, and any applicable health technology assessments to support the medical necessity argument.

Attach pertinent literature or guideline excerpts that support the requested intervention for the specific patient presentation
Reference recent systematic reviews, HTAs, and position statements when available

Note

Conservative Treatment Context

Conservative treatment context: many procedures outlined in this policy are considered only after conservative measures have failed. Conservative treatments include pharmacologic therapy (analgesics, NSAIDs, migraine preventives), physical therapy, behavioral interventions, and targeted injections. Duration and adequacy of conservative care should be documented.

Examples of conservative therapies: oral analgesics, anti-inflammatories, migraine preventive medications, physical therapy, and lifestyle measures
Document duration, adherence, and objective measures of treatment failure (e.g., MIDAS, MSQ)

Note

Conservative-First Expectation

Conservative-first expectation: surgical or device-based interventions are typically considered only after an adequate trial of non-invasive and minimally invasive options has failed. Document the timeline and objective outcome measures demonstrating inadequate response to conservative care prior to authorization or scheduling.

Adequate trial examples: multiple conservative medication trials and nonpharmacologic therapies over a clinically appropriate duration
For neurostimulation, document failure of standard medical and interventional therapies before trial implantation

Prior Authorization

Conservative Therapy and Trial Requirements Before Neurostimulation

Conservative therapy before neurostimulation: prior to considering occipital nerve stimulation or other implanted stimulators, document failure of medical management, appropriate interventional trials (e.g., diagnostic blocks), and a successful temporary stimulation trial when used to select permanent implantation candidates.

Document medical management attempts and outcomes, diagnostic block responsiveness, and results of any temporary neurostimulation trial (including % pain reduction and duration)
Include specialty consultation (pain or neurology) supporting permanent implantation

Systematic reviews recommend prior failure of conservative therapies before surgery due to limited evidence base.

Failure of appropriate conservative management prior to considering surgery, RFA, or neurostimulation

Failure of conservative management: Consideration of RFA, pulsed RFA, or neurostimulation should follow documented failure of appropriate conservative management and specialist evaluation.

Evidence summaries emphasize these interventions are for medically refractory or intractable cases after conservative therapy failure.

Documented failure of conservative medical management prior to implantable neurostimulation is expected

Implantable neurostimulation prerequisites: Permanent implantable neurostimulation (e.g., ONS) is typically considered only after documented failure of conservative therapies and typically after a positive temporary trial demonstrating benefit.Positive temporary trial commonly defined as ≥50% pain reduction

Hayes reports and clinical series selected patients based on trial response; document trial response in prior authorization records.

Conservative therapy and diagnostic block prior to invasive procedures

Diagnostic block before RFN: Diagnostic occipital nerve blockade should precede therapeutic radiofrequency neurotomy; other potential etiologies should be excluded by imaging (MRI/CT) when indicated.

Best practices summary recommends diagnostic blockade before RFN and imaging to rule out other causes.

Conservative therapy expectation: Trials of and inadequate response to medical therapies are expected before considering invasive neuromodulation or surgical procedures.

Standard medical therapies include analgesics, triptans, preventive medications and CGRP inhibitors per policy.

Document trial and response to conservative medical therapy prior to invasive procedures when applicable.

Document medical therapy trials: Document trials of standard acute and preventive headache therapies (e.g., analgesics, triptans, antiemetics, beta blockers, calcium-channel blockers, tricyclic antidepressants, antiepileptics, CGRP inhibitors) and the clinical response prior to authorization of invasive procedures when applicable.

Policy cites these as usual first-line options prior to invasive interventions.

Placeholder for plan-specific conservative treatment expectations

Plan-specific benefit confirmation: Confirm member-specific federal, state, and contractual benefit plan requirements when applying conservative treatment expectations; plan terms may modify or govern coverage decisions.

Instructions for Use state federal/state/contractual requirements govern in case of conflict.

Chronic-repeat GONB for long-term prevention lacks strong supportive evidence and should be considered investigational absent robust documentation.

Recommended documentationIf repeat injections are proposed, document prior conservative therapy responses and rationale given limited long-term data.

C2 DRG pulsed RFA and other RFA procedures — frequency guidance

Frequency limits statedNo explicit numeric frequency limits for C2 DRG pulsed RFA or other RFA procedures are provided in this section.

Evidence on repeat useStudies report variable durations of benefit; candidacy and timing for repeat procedures are guided by clinical judgment and study protocols rather than a set numeric limit.

Documentation expectationPrior positive diagnostic block response and conservative therapy failure should be documented before RFA per best-practice guidance.

Pulsed radiofrequency treatments — frequency guidance

Frequency limits statedThe policy does not provide explicit numeric frequency limits for pulsed radiofrequency (PRF/PRFN) treatments.

Observed duration of effectSystematic reviews report analgesic benefit from PRFN lasting approximately 3–6 months for some headache indications, but optimal repeat timing is unclear.

RecommendationUse and repeat PRF should be guided by clinical response, prior block results, and the limited quality of available evidence; larger RCTs are needed to define protocols.

Repeat RFN sessions — evidence on duration of relief

Evidence on repeat RFNSeveral studies have documented pain relief for up to six months following occipital nerve radiofrequency neurotomy (RFN).

Policy recommendation on repeatsLonger follow-up is needed before routinely recommending repeat RFN sessions; repeat procedures should be considered case-by-case with documentation of prior benefit.

Pre-procedure requirementsDiagnostic occipital nerve blockade and imaging to exclude alternative etiologies are recommended prior to RFN and before considering repeat sessions.

Procedures requiring special arrangements — frequency and oversight

Frequency limits statedFor procedures identified by guideline bodies as requiring 'special arrangements' (e.g., transcutaneous SON stimulation, ONS), the policy does not specify numeric frequency limits.

Governance expectationUse should occur with appropriate clinical governance, informed consent, audit, or within research settings as recommended by NICE and other guidance.

Monitoring implicationProcedures under special arrangements should be audited and reviewed; frequency and repeat use are subject to governance and local review rather than a fixed policy limit.

Include any imaging used to support surgical indication in the authorization record.

Billing Rule

Image guidance expected for RFA/PRF/SPG and occipital/C2 procedures — document modality

Image guidance (ultrasound, CT, or fluoroscopy) is commonly used for RFA, pulsed RF, SPG procedures, and occipital/C2 interventions; document the modality used.

Studies report use of ultrasound or CT/fluoroscopy depending on the procedure.
Record image guidance modality (US, CT, fluoroscopy) in procedure documentation.

Billing Rule

PRFT and other image‑guided interventions — imaging modality varies; document technique

Image guidance practices vary across studies (e.g., CT‑guided PRFT of the sphenopalatine ganglion); when image guidance is used, include the technique in documentation to support the procedure.

Small PRFT SPG studies used CT guidance; image guidance is procedure‑specific and variable.
Document the specific image guidance protocol employed for the intervention.

Documentation Required

MRI/CT recommended to exclude other causes before occipital nerve RFN

Before occipital nerve RFN, MRI and/or CT should be used to exclude other causes when indicated; include imaging reports in the prior authorization or medical record.

Imaging is not diagnostic for occipital neuralgia but helps exclude alternative etiologies prior to RFN.
Attach MRI/CT reports when used to support the indication for RFN.

Documentation Required

Consider neuroimaging in initial cluster headache evaluation — document results

For initial evaluation of cluster headache, consider neuroimaging as part of diagnostic workup when clinically indicated; document imaging decisions in the record.

NICE recommends discussing the need for neuroimaging for first presentation of cluster headache with a clinician with interest in headache or a neurologist.
Document the discussion and any imaging performed.

Note

Confirm plan‑specific imaging requirements before procedure

Providers should reference plan‑specific imaging rules and this policy when planning imaging for interventions; check member benefit terms for any imaging requirements.

Policy advises verifying plan‑specific requirements regarding imaging prior to authorization or procedure.
Document adherence to plan imaging rules when submitting requests.

MIDAS — questionnaire and score categories

Instrument descriptionMIDAS is a questionnaire that measures headache-related disability by summing days from questions 1–5.

Score categories0–5 none/minimal; 6–10 mild; 11–20 moderate; 21+ severe.

Actionable thresholdMIDAS score ≥ 6 indicates need for discussion with a provider.

MSQ — migraine‑specific quality of life questionnaire

Instrument descriptionMSQ is a 14‑item self‑report measure assessing migraine impact across role, emotional, and social functioning using a 6‑point Likert scale.

DomainsAssesses role functioning, emotional functioning, and social functioning to quantify quality‑of‑life impact of migraine.

Use in documentationMSQ is referenced as a patient‑reported outcome to support clinical rationale and assessment of treatment effect.

Neurectomy — definition

DefinitionNeurectomy: partial or total excision or resection of a nerve.

Clinical use noteListed among surgical options studied for occipital neuralgia and related headaches; long‑term efficacy not established in well‑designed trials.

Coding contextSurgical neurectomy procedures are referenced in the policy's surgical intervention discussions and exclusions when evidence is insufficient.

Rhizotomy — definition

DefinitionRhizotomy: surgical section of a nerve root to relieve pain.

Clinical contextIncluded among invasive surgical procedures evaluated for occipital neuralgia and cervicogenic headache; evidence is limited.

ImplicationRhizotomy is considered investigational/unsupported for routine treatment absent strong trial evidence.

Greater occipital nerve block (GONB) — definition

DefinitionGreater occipital nerve block (GONB): injection of local anesthetic, sometimes with corticosteroid, around the greater occipital nerve for diagnostic or therapeutic head pain relief.

Clinical rolesUsed both diagnostically and therapeutically; trials show short‑term reductions in headache intensity and frequency but limited long‑term preventive evidence.

Evidence noteSystematic reviews report short‑term benefit (hours to ~1 month) and heterogeneity across studies; corticosteroid addition generally not shown to add benefit in some analyses.

Occipital neurectomy / nerve decompression — definition

DefinitionOccipital neurectomy/nerve decompression: surgical excision or decompression of occipital sensory nerves intended to treat occipital neuralgia or related headaches.

Evidence cautionLong‑term benefit has not been established in well‑designed clinical trials; considered insufficient evidence for routine use.

Policy implicationOften considered investigational or not medically necessary outside of defined research or refractory contexts without compelling documentation.

Radiofrequency ablation (RFA) — definition

DefinitionRadiofrequency ablation (RFA): thermal or pulsed techniques to denervate or modulate peripheral nerves (e.g., occipital, C2, sphenopalatine ganglion, supraorbital) to reduce headache pain.

Approach variabilityApproaches include pulsed RFA and thermal RFA with variable parameters and targets; device and technique heterogeneity exist across studies.

Evidence noteAvailable evidence is heterogeneous and insufficient to conclusively establish long‑term effectiveness for many headache indications.

Surgical nerve decompression / neurectomy — definition

DefinitionSurgical nerve decompression/neurectomy: surgical procedures aiming to decompress or excise extracranial portions of cranial nerves (e.g., greater/lesser occipital nerves, supraorbital) to treat migraine, occipital neuralgia, or cervicogenic headache.

Outcomes noteSome systematic reviews report substantial reductions in headache days and elimination in a subset of patients at 6–12 months, but studies are small and heterogeneous.

Evidence cautionLong‑term efficacy and generalizability require further high‑quality RCTs before routine endorsement.

Occipital nerve stimulation (ONS) — definition

DefinitionOccipital nerve stimulation (ONS): implanted electrical stimulation applied to occipital nerves intended to reduce refractory headache disorders.

Selection criteriaPermanent implantation is typically considered after documented failure of conservative therapies and a positive temporary trial (commonly ≥50% pain reduction).

Evidence and safetyEvidence is limited and variable; reported responder rates and device‑related complications (lead migration, infection) vary across studies.

Pulsed radiofrequency (PRF/PRFN) — definition

DefinitionPulsed radiofrequency (PRF/PRFN): a nondestructive neuromodulation technique applied to peripheral nerves (e.g., greater occipital nerve) intended to reduce headache intensity and frequency.

Duration of effectSystematic reviews report benefit lasting months (commonly 3–6 months) for chronic migraine and occipital neuralgia in some studies.

Evidence limitationOptimal parameters, targets, and long‑term outcomes remain unclear due to low‑quality, heterogeneous studies.

Remote electrical neuromodulation (REN) — definition

DefinitionRemote electrical neuromodulation (REN): a noninvasive device‑based preventive treatment for migraine that delivered active stimulation to limbs and showed superiority to sham in reducing migraine days in a multicenter RCT.

Trial evidenceA randomized multicenter trial (N=248) demonstrated REN reduced migraine days and medication use versus placebo with no serious device‑related adverse events reported.

RoleConsidered a nonpharmacologic preventive or acute therapy alternative based on device‑specific trial evidence.

Occipital nerve stimulation (ONS) — additional definition

DefinitionOccipital nerve stimulation (ONS) — additional: an implantable peripheral nerve stimulation system targeting occipital nerves for refractory headaches; often selected after positive temporary trial.

Outcomes variabilityResponder rates and complication profiles vary widely across studies; selection typically by specialists in tertiary settings.

Evidence noteGuidance recommends careful patient selection and documentation of trial response prior to permanent implantation.

RFN (occipital neurotomy) — definition

DefinitionRFN (occipital neurotomy): targeted radiofrequency thermal lesioning of greater or lesser occipital nerves to treat posterior head pain after diagnostic blocks identify the nerve as the pain source.

Procedure considerationsDiagnostic occipital nerve blockade should precede RFN; MRI/CT to exclude other causes is advised when indicated.

Reported durationSeveral studies documented up to six months of relief following RFN; longer‑term evidence to guide repeat procedures is limited.

ONS — alternate definition (implantable neurostimulation)

DefinitionONS — alternate: invasive implanted neurostimulation system (pulse generator and leads) intended for refractory headache syndromes; selection usually follows a positive temporary stimulation trial.

Adverse eventsDevice‑related complications reported include infection, lead migration/fracture, wound issues, and need for revisions or removal.

Coverage implicationGiven variable evidence and complication rates, ONS is typically reserved for medically refractory cases and may require prior authorization and specialist oversight.

Botulinum toxin A (BTX‑A) — definition and regulatory note

DefinitionBotulinum toxin A (BTX‑A): a neurolytic agent approved by the FDA for certain indications but not specifically for cervicogenic headache or occipital neuralgia; use for those diagnoses is off‑label.

Regulatory noteBTX‑A is FDA‑approved for some conditions; its application to cervicogenic headache or occipital neuralgia is not an approved indication.

Policy implicationUse of BTX‑A for these diagnoses should be documented as off‑label and supported by clinical rationale when considered.

RFA and electrical stimulation devices — regulatory/device note

DefinitionRFA and electrical stimulation devices: devices used to perform RFA or electrical stimulation are regulated via FDA 510(k) or De Novo pathways; product codes and identifiers exist for lesion generators, probes, and stimulation devices.

Device product codesRFA product codes: GXD (radiofrequency lesion generators), GXI (radiofrequency lesion probes). Electrical stimulation product codes: GZF, GZB, PCC; Nerivio identifier K203181 mentioned.

Coverage noteFDA device clearance is informational; clearance alone is not a sole basis for coverage decisions.

MIDAS — added patient‑reported outcome definition (summary of changes)

MIDAS added in revisionsMIDAS definition and use as a patient‑reported outcome were added to the policy (Summary of Changes, 10/01/2025).

Purpose of additionNew definitions support documentation expectations and use of outcome measures in clinical evidence and prior authorization review.

ReferencePolicy history notes the added MIDAS and MSQ definitions in the Summary of Changes dated 10/01/2025.

MSQ — added patient‑reported outcome definition (summary of changes)

MSQ added in revisionsMSQ definition and description were added to the policy (Summary of Changes, 10/01/2025).

Purpose of additionMSQ inclusion supports standardized documentation of migraine‑related quality‑of‑life measures in clinical evidence and authorization reviews.

ReferencePolicy history documents the addition of MSQ to Definitions on 10/01/2025.

Previous policy version CS086PA.X archived.

The policy's Clinical Evidence and References sections have been updated to reflect the most current information, and the Summary of Changes notes the addition of definitions for the Migraine Disability Assessment Test (MIDAS) and the Migraine‑Specific Quality of Life Questionnaire (MSQ) to support documentation and outcome assessment.